



Fact Sheet

Find your candidate, whatever the target demands

PHAGE DISPLAY | MAMMALIAN DISPLAY | SINGLE B-CELL | BI-/MULTI-SPECIFICS



MultiPath Discovery is FairJourney Bio's integrated antibody discovery suite — engineered to deliver developable leads, not just hits

As an antibody discovery expert with more than 1,400 completed projects and 19 partner assets that entered in clinical trials, FJBio combines naive, semi-synthetic and immune libraries with phage, mammalian, yeast and single B-cell platforms in a single integrated and customisable workflow. The result: The most optimal path to candidates for your programme, with developability built in from the start— not addressed after a failed lead. Any target, any format.

BACKGROUND

Why partner with FJBio for MultiPath Discovery

Format-optimised from day one

ScFv, Fab, VHH, VHH-Fc, biparatopic and IgG formats — your biology is leading, no platform constraints.

>5,000 libraries generated

Track record across naive, semi-synthetic, immune and bespoke library strategies, spanning multiple species and donor pools.

Mammalian Display advantage

Patent-protected mammalian display selects for developability, CMC- and functional properties simultaneously during discovery, not after.

Integrated single B-cell

Natively paired VH–VL recovery from 10^6 – 10^7 B-cells per run, including human patient samples.

Tough-target ready

Internalising mAbs, pH-selective binders, dual binders, TCR mimetics, CARs, Fc isotypes and mutants.


Under one roof

Discovery, characterisation, engineering and production handled by one team in one workflow.

Comprehensive modular platforms and integrated workflow

Meeting the challenges


Sources of diversity



Solutions for all applications

Bi- and Multi-specifics and their building blocks
Internalizing mAbs
pH-selective binders

Discovery platforms



Dual Binders
TCR mimetics
CARs
Fc isotypes and mutants

Tool antibodies for target validation (Fab, ScFv, VHH discovery formats)
Clinical-stage assay tools

Final Format



Anti-idiotypic antibodies
Biomarker detection
Sandwich pairs

1,400+

COMPLETED PROJECTS

5,000+

LIBRARIES GENERATED

19

PARTNER ASSETS ENTERED
CLINICAL TRIALS

460,000+

REAL-WORLD SEQUENCES
SOLVED

MultiPath Discovery – Capability Detail

Library types & diversity

- **Naive libraries:** $>10^{10}$ diversity; ScFv, Fab and VHH formats; kappa & lambda repertoires; common light chain option
- **Semi-synthetic libraries:** up to 10^{11} diversity; ScFv format; common light chain option
- **Immune libraries:** 10^6 – 10^9 diversity; phage display and single B-cell antibody recovery; multiple species including human patients
- **Named libraries:** SuperHuman 2.0 ($>76B$ clones, hard-wired for developability), Cosmic (100B clones, optimised for low immunogenicity), Full-framework libraries (up to 50B clones), Explorer (rapid affinity maturation)

Display technologies


- **Phage display:** multiple binder formats; solid-phase, in-solution, cell panning and pH panning
- **Mammalian display:** 10^6 – 10^7 variants per library; display level correlates with CMC properties; patent protected worldwide
- **Yeast display:** 10^7 – 10^8 variants per library; multi-parametric selections in a single workflow (affinity, dual-binding, pH, cross-reactivity)
- **Named libraries:** natively paired VH–VL recovery from the full B-cell immune repertoire; surface Ig and secretory Ig populations

Application breadth

- Bi- and multi-specifics and their building blocks
- Internalising mAbs, pH-selective binders, dual binders, TCR mimetics, CARs
- Fc isotypes and mutants for tailored effector function
- Tool antibodies for target validation, clinical-stage assay tools, anti-idiotypic antibodies, biomarker detection, sandwich pairs

Examples of how FJBio addresses antibody discovery challenges

Against SIRPα, a high-homology target (80% cyno; 87% SIRPβ; 81% SIRPγ), the Cosmic Library delivered broadly-binding, developable leads: 132 of 190 clones were blockers, 22 functional IgGs at low nM, 82%/86% passing T_m / T_{agg} thresholds across 21 epitope bins.



	V1	V2	V3	Cyno-SIRPα	SIRP-Beta	SIRP-Gamma	Ab Count
Bin1							154
Bin2							79
Bin3							21
Bin4							18
Bin5							18
Bin6							15
Bin7							11
Bin8							8
Bin9							5
Bin10							4
Bin11							3
Bin12							2
Bin13							1
Bin14							1
Bin15							1
Bin16							1
Bin17							1
Bin18							1
Bin19							1
Bin20							1
Bin21							1

**One platform, every modality.
Discovery that starts with the clinic in mind, not in retrospect.**

Let's talk about your programme

Bring your target, your timeline and your tough questions to a scoping conversation.

info@fjbio.com | fjbio.com

Porto • Cambridge • San Diego



www.fjbio.com
info@fjbio.com